Related Experiment Video

Updated: May 16, 2026

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
09:47

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery

Published on: June 2, 2022

[Anaesthetic approach of paediatric pulmonary hypertension]

O Desebbe1, J Neidecker, O Bastien

  • 1Service d'anesthésie réanimation, université Claude-Bernard Lyon-1, hôpital cardiologique Louis-Pradel, hospices civils de Lyon, groupement hospitalier Est, 200, avenue du Doyen-Lépine, 69500 Bron, France. olivier.desebbe@chu-lyon.fr

Annales Francaises D'Anesthesie Et De Reanimation
|November 28, 2012
PubMed

Insights

Paediatric pulmonary arterial hypertension (PAH) requires expert anaesthetic care due to high risks. Key goals include maintaining pulmonary blood flow and systemic blood pressure, with haemodynamic monitoring crucial for managing crises.

Area of Science:

  • Cardiology
  • Anaesthesiology
  • Paediatric Medicine

Context:

  • Paediatric pulmonary arterial hypertension (PAH) presents significant challenges in anaesthetic management.
  • The condition is associated with high morbidity and mortality rates in children.
  • A multidisciplinary team approach is essential for optimal patient support.

Purpose:

  • To outline the critical considerations for anaesthetic management in paediatric pulmonary arterial hypertension.
  • To emphasize the importance of understanding PAH pathophysiology for therapeutic strategies.
  • To highlight the objectives of anaesthesia in patients with high pulmonary vascular resistance.

Summary:

  • Anaesthetic management for paediatric PAH focuses on maintaining optimal pulmonary blood flow and avoiding systemic hypotension.
  • Understanding the underlying pathophysiology guides the therapeutic approach.
  • Haemodynamic monitoring is vital for detecting acute PAH crises and assessing treatment effectiveness.

Impact:

  • Improved anaesthetic strategies can reduce morbidity and mortality in paediatric PAH patients.
  • Enhanced understanding of haemodynamics allows for timely intervention during critical events.
  • This approach ensures better outcomes for children undergoing anaesthesia with PAH.

More Related Videos

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

Related Concept Videos

Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...